Genome instability occurs early in the development of most cancers. Bester et al. now provide evidence that oncogenic signals trigger cell division without coordinate nucleotide synthesis, engendering aberrant DNA replication and damage that could promote carcinogenesis. A mismatch between proliferation and metabolite production may characterize oncogenic cell cycles.
Cellular proliferation is a normal and necessary aspect of development and physiological maintenance. Unchecked proliferation, however, leads to cancer. Cells have evolved a series of safeguards, such as tumor suppressors like p53, to guard against abnormal proliferation, but how do cells distinguish between normal and oncogenic cell cycles? One view is that DNA damage is part of the equation because oncogenic stimuli in nonmalignant cells trigger DNA breaks (Bartkova et al., 2005; Gorgoulis et al., 2005) and p53 activation (Serrano et al., 1997) , leading to arrested growth. But it has remained speculative how oncogenic cell cycles might activate the DNA damage response when normal but equally vigorous proliferation does not, although aberrant DNA replication has been implicated circumstantially (Di Micco et al., 2006; Venkitaraman, 2005) . In this issue, Bester et al. (Bester et al., 2011) report provocative findings that may help to close the circle between oncogenic cell cycles and the induction of replication-associated damage.
Bester et al. begin by inappropriately activating the Rb-E2F pathway, a network of proteins that normally monitors entry into the cell division cycle and is very frequently altered in cancers. They employ primary cultures of human keratinocytes from skin biopsies in which no genetic alterations permissive for neoplastic transformation are likely to pre-exist. This deserves emphasis because many prior studies have relied either on cancer cell lines or immortalized but nontransformed cell lines. Although cell lines of these types may possess intact p53, they will almost indubitably have genetic alterations affecting other tumor suppressor pathways to permit unceasing growth in culture. These additional alterations may have made it more difficult in prior work to spot the differences between normal and oncogenic cell cycles. Bester et al. activate the Rb-E2F pathway either by introducing into the keratinocytes the E6 and E7 oncoproteins from human papillomavirus (HPV), a cause of human cervical cancer, or by overexpressing cyclin E, an event characteristic of breast and other epithelial tumors.
The authors analyze the progress of DNA replication in keratinocytes exposed to these oncogenic challenges using DNA fiber combing. Consistent with the prior results, they find that there is a marked decrease in the rate and symmetry of replication fork progression away from replication origins when the Rb-E2F pathway has been activated by E6/E7. Also in accordance with previous results, Bester et al. show that these anomalies in replication are followed by increasing evidence of instability at genomic sites thought particularly vulnerable to replication-associated damage (''fragile sites''), such as loss of heterozygosity or copy number variation. So far, these results provide unsurprising but welcome confirmation that oncogenic activation of the Rb-E2F pathway is sufficient to trigger aberrant replication and genome instability in primary cell cultures. The authors go on to show that the cells exhibit an enhanced propensity for colony outgrowth in soft agar. These results raise a number of questions that remain topics for future study. For example, how do oncogene-challenged keratinocytes survive and divide for so long in the face of continuing DNA damage? Must the cells overcome checkpoint activation and/or apoptosis to do this, and if so, how do these selective pressures influence the observed genomic instability?
These issues aside, the most provocative and interesting thread in this study, in this author's view, begins with the authors' surprising finding that E6/E7-bearing keratinocytes exhibit a 2-to 5-fold decrease in their content of all four dNTPs. Supplementing the culture media with exogenously supplied nucleosides was sufficient to reverse the observed decrease in replication fork progression induced by E6/E7 or cyclin E, suggesting a causal connection. This appears to be specific to cells undergoing the oncogenic challenge because nucleoside supplementation had little effect on replication dynamics in donormatched but unchallenged keratinocytes. Nucleoside supplementation was enough not only to restore normal replication parameters in the E6/E7-or cyclin E-expressing cells, but also to prevent DNA breakage marked by phosphorylation of histone H2AX and to suppress the outgrowth of colonies in soft agar.
Bester et al. then attempt to uncover why nucleotide deficiency is apparently associated with oncogenic cell cycles. In this regard, their results are suggestive, but not yet definitive. The authors find that cells in which the Rb-E2F pathway has been activated by E6/E7 or cyclin E upregulate the transcription of genes that participate in the cell division cycle and DNA replication but, significantly, failed to alter the synthesis of most of the genes required for rate-limiting steps in nucleotide synthesis. The authors thus speculate that the uncoordinated regulation of genes involved in proliferation without the concomitant elevation of nucleotide synthesis genes forces cells to replicate their DNA under suboptimal conditions, leading to replication anomalies and, eventually, DNA damage.
The authors find that enforced expression of c-Myc (Liu et al., 2008; Mannava et al., 2008) can prevent the replication anomalies induced by oncogenic challenge and even inhibit colony formation in soft agar. Notably, the apparently anti-oncogenic effect of c-Myc expression in this setting contrasts with its frequent overexpression in later-stage tumors, which is apparently required for their continued outgrowth (Soucek et al., 2008) . The significance of the anti-oncogenic role of c-Myc expressed heterologously in this way remains unclear. Not only does the experiment leave open the possibility that effects of c-Myc other than on nucleotide biosynthesis are responsible, but it also suggests that c-Myc is not induced, at least initially, during oncogene-driven growth, as it normally is during programmed cell proliferation, which is puzzling.
Indeed, this last point suggests a tantalizing hypothesis that cellular proliferation in response to normal stimuli like growth factors may induce a coordinate and appropriate transcriptional program, driven by c-Myc or other factors, sufficient to sustain DNA replication (Figure 1, top) . In contrast, oncogenic stimuli may work downstream of c-Myc and the other factors induced during normal proliferation, leading to an insufficiency of genes like those necessary for nucleotide biosynthesis (Figure 1, bottom) . Not only could this mismatch force cells to carry out DNA replication under suboptimal circumstances, as shown by Bester et al., but it could also provoke further ''stress'' reactions when cells attempt to execute other metabolic activities usually associated with proliferation but without the benefit of the function of c-Myc or other factors, eliciting a variety of cellular anomalies during oncogene-driven proliferation. Cells probably use several different tumor-suppressive pathways to detect these anomalies. This may help to explain why different tumor suppressors like ARF as well as p53, for instance, appear to play nonoverlapping roles in arresting oncogene-induced proliferation (Lowe et al., 2004 During normal proliferation elicited, for example, by growth factor stimulation (top), cellular programs leading to DNA replication are coordinated with nucleotide biosynthesis and other metabolic programs that are necessary to sustain growth through the action of c-Myc or other factors. In contrast, oncogenic stimuli (lightning bolt, bottom) may work downstream to activate cell division, bypassing the metabolic programs that are associated with normal growth. This forces DNA replication to proceed under suboptimal conditions such as nucleotide deficiency, engendering aberrations that cause DNA damage leading to genome instability. Similarly, other metabolic deficiencies associated with oncogene-driven proliferation could evoke different cellular stress reactions detected by tumor suppressors like p53 or ARF, which might promote carcinogenesis if left undetected.
